Prostate cancer is among the most commonly diagnosed cancers in men, affecting approximately one in eight during a lifetime. Although many patients can be successfully treated, the disease becomes far more difficult to control after it spreads beyond the prostate. In the United States, prostate cancer remains the second-leading cause of cancer-related death in men. Most prostate tumors initially resemble normal prostate glands and retain a dependence on androgens, the male sex hormones that include testosterone. This biological dependence makes the androgen receptor an important treatment target. Drugs that block androgen production or prevent androgen receptor signaling are therefore central to the management of metastatic prostate cancer.

The initial response to androgen receptor inhibitors can be substantial, but resistance eventually develops in nearly all patients with advanced disease. Some tumors continue growing by finding alternative ways to activate androgen receptor signaling. Others take a more radical route: they reprogram their identity. Instead of maintaining the features of gland-forming prostate cells, these cancers may acquire characteristics associated with stem-like, neuroendocrine or other cellular states. This process, known as transdifferentiation, involves extensive changes in gene expression and cellular behavior. The resulting tumors are often less dependent on androgen signaling and may become far more difficult to detect and treat using conventional prostate cancer therapies.

The Michigan team focused on tumors in which two major tumor-suppressor genes, TP53 and RB1, have been lost. Previous research had connected the disappearance of these genes with prostate cancer transdifferentiation, but the molecular logic behind that association remained unclear. By comparing prostate cancer cell lines with different genetic backgrounds, the researchers found that the transition appeared to involve two coordinated processes. First, cells shut down genes associated with glandular prostate function. At the same time, they activated gene-regulatory programs linked to stem-cell-like identities and alternate developmental states. Rather than representing a single molecular switch, transdifferentiation appears to be a coordinated rewiring of the cancer cell’s regulatory system.

This distinction helped explain why an earlier therapeutic approach had only limited success. The researchers had previously shown that BET bromodomain inhibitors could interfere with the activation of alternate identity programs. BET proteins help control gene expression by recognizing acetylated histones, the proteins around which DNA is packaged. By disrupting these interactions, BET inhibitors can reduce the transcription of selected cancer-promoting programs. In the new study, however, the drugs slowed the growth of transdifferentiated prostate cancer cells without consistently killing them. The surviving cells retained enough flexibility to maintain the altered state and eventually continue progressing, suggesting that blocking the activation of new programs was not sufficient by itself.

The investigators therefore added DNMT inhibitors to the treatment strategy. DNA methyltransferases place chemical tags called methyl groups onto DNA, often reducing the activity of nearby genes. In cancer, abnormal DNA methylation can silence genes that would otherwise help maintain normal cellular identity or restrain tumor growth. DNMT inhibitors can remove or dilute some of these methylation marks as cells divide, allowing previously silenced genes to become active again. The drugs are already approved by the U.S. Food and Drug Administration for certain blood cancers, but their potential in transdifferentiated solid tumors remains under investigation. In this study, the researchers reasoned that DNMT inhibition might help restore glandular gene programs while BET inhibition suppressed the alternate programs supporting the transformed identity.

The combined treatment produced stronger effects than either drug alone in prostate cancer cell lines. According to the researchers, the two-drug regimen reduced cancer cell growth and reversed a substantial portion of the gene-expression changes associated with transdifferentiation. The results were also reproduced in mice carrying implanted tumors, where the combination slowed tumor growth more effectively than individual treatment. Notably, the researchers reported significant antitumor activity at doses lower than the recommended doses of the individual drugs, and the regimen was well tolerated by the animals. These findings suggest that the drugs may operate through complementary mechanisms: one limits the transcriptional machinery that sustains the abnormal cell state, while the other helps reactivate genes lost during the transition.

The study remains preclinical, and the results do not yet demonstrate that the combination is safe or effective in people with advanced prostate cancer. Epigenetic drugs can affect gene activity across many tissues, creating the possibility of side effects that may not be apparent in laboratory models or short-term animal experiments. The researchers are now working to determine which individual genes are responsible for the treatment response and whether molecular biomarkers can identify patients most likely to benefit. Such biomarkers could include patterns of TP53 and RB1 loss, DNA methylation signatures, or gene-expression profiles indicating that a tumor has begun adopting a stem-like or non-glandular identity.

An additional goal is to intervene before transdifferentiation becomes established. Once prostate cancer cells have fully shifted into an alternate state, they may be more adaptable and resistant to therapies designed for conventional glandular tumors. Detecting early signs of the transition could allow clinicians to use combination treatment before the cancer becomes deeply reprogrammed. The Michigan researchers also believe that the strategy may have relevance beyond prostate cancer. Similar forms of lineage plasticity and transdifferentiation are being studied in lung and pancreatic cancers, where tumor cells can escape treatment by changing their biological identity. If future studies confirm the mechanism, simultaneous targeting of epigenetic survival programs could become a broader strategy for cancers that evolve by rewriting their cellular blueprint.

Subject of Research: Animals

Article Title: Combined BET bromodomain and DNMT inhibition targets critical survival pathways in transdifferentiated prostate cancer

News Publication Date: 11-Aug-2026

Web References: https://insight.jci.org/articles/view/207543; https://doi.org/10.1172/jci.insight.207543

References: JCI Insight, “Combined BET bromodomain and DNMT inhibition targets critical survival pathways in transdifferentiated prostate cancer,” DOI: 10.1172/jci.insight.207543

Keywords: prostate cancer, metastatic prostate cancer, transdifferentiation, treatment resistance, androgen receptor inhibitors, BET bromodomain inhibitors, DNMT inhibitors, epigenetics, TP53, RB1, tumor suppressor genes, cancer cell identity, prostate cancer therapy, University of Michigan, JCI Insight

Prostate cancer remains a leading cause of cancer morbidity and mortality worldwide, with therapeutic resistance and tumor heterogeneity posing formidable barriers to curative treatment. Conventional therapies, including androgen deprivation and chemotherapy, often succumb to resistance mechanisms. Targeted radioligand therapy (RLT) targeting PSMA has gained traction due to PSMA’s almost exclusive and abundant expression on prostate cancer cells, facilitating selective delivery of cytotoxic agents. The alpha-emitter lead-212, with its high linear energy transfer and short path length, offers potent localized DNA damage, minimizing off-target effects and enhancing therapeutic index.

The study meticulously engineered the radioligand [^212Pb]Pb-AB001 to leverage PSMA’s tumor-specific expression. By conjugating lead-212 to the AB001 molecule, researchers harnessed the alpha particle emissions to induce irreparable double-strand breaks in DNA within prostate cancer cells, triggering apoptosis. Despite the impressive cytotoxic potential, monotherapy with targeted alpha radioligands often faces limitations, including suboptimal efficacy in heterogeneous tumor microenvironments and cellular survival adaptations that blunt responses.

Recognizing this, the research team investigated the combinatorial use of BET bromodomain inhibitors, compounds that interfere with epigenetic readers involved in regulating gene expression critical for cancer cell survival and proliferation. BET proteins, particularly BRD4, facilitate transcription of oncogenes and pathways integral to tumor growth. Pharmacological inhibition impairs these transcriptional programs, sensitizing cancer cells to DNA damage and disrupting repair mechanisms.

In vitro models of prostate cancer treated with the [^212Pb]Pb-AB001 radioligand exhibited significant cell death, corroborating prior evidence of alpha radiation’s lethality. However, when combined with BET inhibitors, the prostate cancer cell lines showed markedly enhanced cytotoxicity, surpassing additive effects and implying synergy. This dual approach not only delivered direct DNA damage but simultaneously suppressed the transcriptional machinery required for adaptive responses and DNA repair, effectively preventing cancer cells from mounting resistance strategies.

Mechanistically, the synergy appears rooted in the disruption of DNA damage response by BET inhibition. Normally, prostate cancer cells may activate compensatory pathways, such as homologous recombination or non-homologous end joining, to repair radiation-induced DNA lesions. BET bromodomain inhibitors compromise these pathways by downregulating key repair proteins and oncogenic drivers, thereby locking the cells into a fatal DNA damage state induced by alpha-particles. This convergent attack devastates cellular viability more comprehensively than either modality alone.

This research also highlights the importance of PSMA as a vehicle for precise delivery. The biodistribution and selectivity conferred by the AB001 ligand ensure that alpha emissions preferentially localize within PSMA-expressing tumor sites, mitigating collateral normal tissue toxicity. This targeted approach is especially significant given the potency of alpha-emitters and their potential for hematologic and renal toxicities if misdirected.

Furthermore, the study’s use of the radioisotope lead-212 provides advantageous decay kinetics for clinical translation. With a half-life of approximately 10.6 hours, it offers a balance between sufficient time to localize in tumors and rapid decay to limit prolonged radiation exposure. Additionally, lead-212 decays to alpha-emitting bismuth-212, further enhancing therapeutic payload without increasing off-target risks.

Despite these encouraging preclinical findings, the scientists underscore that in vitro data is a foundational but initial step. Translating the combined therapy into in vivo systems and ultimately clinical settings entails navigating complex pharmacodynamics, dosimetry, and toxicity profiles. Nonetheless, the anticipation is that this fusion of targeted alpha radioligands with epigenetic inhibitors could substantially extend the therapeutic window for advanced prostate cancer patients, particularly those with castration-resistant disease.

Moreover, the conceptual framework established here invites potential exploration in other malignancies expressing tumor-specific antigens amendable to alpha radioligand targeting. Integrating epigenetic modulation to disable cancer cell plasticity and repair could be a transformative theme across oncology therapeutics, reinvigorating radiopharmaceutical development strategies.

This investigation is also notable for advancing precision medicine paradigms. By exploiting the molecular vulnerability of PSMA and combining distinct mechanistic classes—radiotherapy and epigenetic therapy—it exemplifies how rational drug design can create synergistic regimens that overcome monotherapy limitations. The work stands as a testament to interdisciplinary collaboration among radiochemists, molecular biologists, and oncologists.

Importantly, the use of bromodomain inhibitors is not without challenges, including off-target effects and development of resistance mutations. However, their transient application alongside a potent radioligand could mitigate long-term toxicities while maximizing cancer cell eradication. Future studies might optimize dosing schedules, evaluate biomarkers predictive of response, and assess combinatorial toxicities in sophisticated preclinical models.

Clinical trials stemming from this line of research hold promise to redefine salvage options for patients with metastatic prostate cancer, a setting where new effective therapies are critically needed. Given the escalating incidence of prostate cancer worldwide and the increasing recognition of PSMA as a versatile therapeutic target, the impact of such novel combination therapies could be monumental.

In summary, the study by Liukaityte and colleagues pioneers a compelling avenue in prostate cancer treatment by uniting the targeted cytotoxic power of a lead-212 labeled PSMA radioligand with the transcriptional silencing capabilities of BET bromodomain inhibitors. Through rigorous in vitro experimentation, they demonstrate enhanced prostate cancer cell killing that offers a new therapeutic blueprint. As research progresses, this synergistic strategy may well usher in a new era of alpha-radioligand therapies with augmented potency and precision.

Given the urgent clinical demand to improve outcomes in aggressive prostate cancers and overcome resistance mechanisms, the integration of novel alpha-emitting radiopharmaceuticals with epigenetic agents represents one of the most exciting frontiers in oncology today. The convergence of these two modalities exemplifies how innovative molecular targeting can transform cancer therapy, laying the groundwork for future translational success and ultimately improving patient survival and quality of life.

Subject of Research: Combination therapy targeting prostate cancer using PSMA-targeted alpha-emitting radioligand [^212Pb]Pb-AB001 and BET bromodomain inhibitors.

Article Title: Combination of PSMA targeting alpha-emitting radioligand [^212Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models.

Article References:
Liukaityte, R., Stenberg, V.Y., Kleinauskas, A. et al. Combination of PSMA targeting alpha-emitting radioligand [^212Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models. Med Oncol 42, 362 (2025). https://doi.org/10.1007/s12032-025-02925-9

Image Credits: AI Generated